Sigma-tau SpA Dihydroartemisinin/Piperaquine 15 November 2010 Application for Inclusion in the 17th WHO Model List of Essential Medicines APPLICATION FOR INCLUSION OF DIHYDROARTEMISININ…

1. Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology Clinical Research 2. Agenda Basis for the accelerated approval…

Slide 1Workshop 4: Il late-presenter Moderatori: G. Ippolito, M. Moroni Discussant: R. Iardino Risposta virologico-clinica e scelta della terapia C. Mussini Slide 2 760 pazienti/…

Slide 1ISSUES THAT PLAGUE NON- INFERIORITY TRIALS PAST AND FUTURE RALPH B. DAGOSTINO, SR. BOSTON UNIVERSITY HARVARD CLINICAL RESEARCH INSTITUTE Slide 2 OBJECTIVES 1.REVIEW…

Slide 1James Hung, 2004 FDA/Industry Management of Missing Data in Clinical Trials from a Regulatory Perspective H.M. James Hung Div. of Biometrics I, OB/OPaSS/CDER/FDA Presented…

Slide 1CLINICAL & COST- EFFECTIVENESS OF NEURAMINIDASE INHIBITORS FOR THE TREATMENT & PREVENTION OF INFLUENZA Nicola Cooper, PhD & Alex Sutton, PhD Centre for…

1. CHAMPION PLATFORM Deepak L. Bhatt, MD, MPH, A. Michael Lincoff, MD, C. Michael Gibson, MS, MD, Gregg W. Stone, MD, Steven McNulty, MS, Gilles Montalescot, MD, PhD,Neal…

Slide 1 A turning point in adjuvant therapy: Optimizing use of aromatase inhibitors P Pronzato Genova Slide 2 Invasive Breast Cancer by Age and ER-PR status. (Year 1998)…

Intermediate stage HCC treatment options: TACE + sorafenib 1. Llovet JM, et al. Lancet. 2002;359:1734-9. 2. Lo C-M, et al. Hepatology. 2002;35:1164-71. TACE: long-term survival…

RECIST Overview Training slides RECIST Overview Introduction What is RECIST? RECIST Endpoints in Berenice Definitions Methods of Assessment Schedule of Assessments Evaluation…